Pharma Mar company profile
Company profile
Pharma Mar has 505 employees and is headquartered in Madrid, Spain.
Pharma Mar, S.A. is based in Madrid, Spain, where it was incorporated in 1986. The biopharmaceutical company researches, develops, produces and commercializes bio-active compounds for oncology, selling its treatments in Spain, Germany, Ireland, France, Switzerland, the rest of the European Union, the United States and other markets. Its best-known products include Yondelis, for soft tissue sarcoma and ovarian cancer, Zepzelca, for small cell lung cancer, and Aplidin, for multiple myeloma. Its pipeline includes candidates in Phase I to Phase III trials for solid tumors, metastatic leiomyosarcoma and small cell lung cancer, as well as an early-stage program for eye diseases such as age-related macular degeneration. The group also works in RNA interference, developing therapies based on reducing or silencing gene expression.
In the fiscal year ended December 2025, revenue reached 221.4 million euros, up 26.6% from the previous year, and net profit was 75.0 million euros. The company employed 505 people.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Spain
- Headquarters
- Avenida de los Reyes, 1, 28770, Madrid
- Employees
- 505
- Chief executive
- Jose Fernandez Sousa-Faro
- Founded
- 1986
- Fiscal year
- January - December
- Listing
- PHM · BME
- Currency
- EUR
- ISIN
- ES0169501022
- Website
- pharmamar.com
Pharma Mar and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Pharma MarPHM | Spain | $1.29B | 505 | 21.3% | 17.2 |
| IdorsiaIDIA | Switzerland | $1.26B | 424 | -68.4% | — |
| Basilea PharmaceuticaBSLN | Switzerland | $1.07B | 200 | 24.2% | 18.1 |
| PhilogenPHIL | Italy | $920.79M | 230 | 79.1% | 4.01 |
| InventivaIVA | France | $895.83M | 87 | -5,980.9% | — |
| Pharming GroupPHARM | Netherlands | $892.54M | 407 | 12.8% | 38.0 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
